Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-003147-19-GR (EUCTR)	18/07/2016	25/05/2016	To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS).	Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Controlled, Add-on with Interferon Beta, Trial of Efficacy and Safety. - Efficacy and Safety study of NEUROASPIS PLP10® versus placebo	Relapsing-Remitting Multiple Sclerosis (RRMS) MedDRA version: 19.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: NEUROASPIS PLP10® INN or Proposed INN: FISH OIL ,RICH IN OMEGA 3 ACIDS Other descriptive name: FISH OIL , RICH IN OMEGA-3-ACIDS INN or Proposed INN: BORAGE OIL 20% GLA Other descriptive name: BORAGE OIL INN or Proposed INN: beta-Carotene Other descriptive name: BETACAROTENE INN or Proposed INN: Gamma-tocopherol	PALUPA Medical Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	220	Phase 3	Greece
2	NCT02133664 (ClinicalTrials.gov)	June 2014	6/5/2014	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Multiple Sclerosis;Cognition	Drug: lipoic acid and omega-3 fatty acids;Drug: Placebo	Oregon Health and Science University	National Multiple Sclerosis Society	Completed	18 Years	65 Years	All	54	Phase 1/Phase 2	United States
3	NCT00360906 (ClinicalTrials.gov)	December 2004	4/8/2006	Omega-3 Fatty Acid Treatment in Multiple Sclerosis	Omega-3 Fatty Acid Treatment in Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: Triomar™ (omega-3 fatty acids)	Haukeland University Hospital	The Multiple Sclerosis National Competence Centre;The Norwegian Multiple sclerosis Society;Pronova BioPharma;Serono Nordic;Amersham Health	Completed	18 Years	55 Years	Both	100	Phase 2/Phase 3	Norway